May 23, 2023 03:15 PM EDTUpdated June 12, 01:38 PM
Pharma
Law

Am­gen, Janssen reach set­tle­ment on Ste­lara biosim­i­lar drug, al­low­ing for 2025 launch at lat­est

Paul Schloesser

Associate Editor

Am­gen and Janssen set­tled their law­suit over a biosim­i­lar op­tion to J&J’s block­buster bi­o­log­ic Ste­lara — paving the way for the new­er drug to en­ter the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times